Skip to main content
Premium Trial:

Request an Annual Quote

Genome Institute of Singapore, OBD Collaborate on Stem Cell Epigenetic Signatures

NEW YORK (GenomeWeb News) – The Genome Institute of Singapore today announced an agreement with Oxford Biodynamics to identify epigenetic signatures in stem cells.

The collaboration leverages OBD's EpiSwitch biomarker discovery platform, which allows researchers to discover and monitor highly specific epigenetic biomarkers called chromosome conformation signatures. These biomarkers define and control important elements of epigenetic and gene regulation.

UK-based OBD said on its website that EpiSwitch uses a machine-learning algorithm to identify DNA patterns "that are likely to form higher order structures. The algorithm tracks implicit information embedded in the genome that probably signifies the borders of transcription units."

GIS added that EpiSwitch can differentiate or confirm the epigenetic footprint of induced pluripotent stem cells (IPSC), embryonic stem cells, or progenitor cells from representative cell lines. In the first application of the platform under today's deal, EpiSwitch biomarkers "will provide a quick and efficient tool to monitor the quality and safety of IPSCs," said GIS, an institute of the Agency for Science, Technology and Research.

Financial and other terms of the deal were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.